Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) saw an uptick in trading volume on Friday . 2,632,187 shares traded hands during mid-day trading, an increase of 207% from the previous session’s volume of 858,547 shares.The stock last traded at $10.17 and had previously closed at $10.07.

Several brokerages have recently issued reports on SPPI. HC Wainwright reiterated a “buy” rating and issued a $14.00 price objective on shares of Spectrum Pharmaceuticals in a research note on Thursday. Zacks Investment Research cut Spectrum Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Friday, August 18th. ValuEngine upgraded Spectrum Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Thursday, August 17th. Jefferies Group LLC set a $9.00 price objective on Spectrum Pharmaceuticals and gave the company a “buy” rating in a research note on Friday, August 25th. Finally, BidaskClub cut Spectrum Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Monday, July 31st. Two analysts have rated the stock with a hold rating and five have issued a buy rating to the company. The company has an average rating of “Buy” and an average price target of $10.80.

The firm has a 50 day moving average of $9.28 and a 200-day moving average of $7.35. The firm’s market capitalization is $799.12 million.

Spectrum Pharmaceuticals (NASDAQ:SPPI) last issued its quarterly earnings results on Thursday, August 3rd. The biotechnology company reported ($0.26) EPS for the quarter, beating analysts’ consensus estimates of ($0.27) by $0.01. The firm had revenue of $34.30 million during the quarter, compared to the consensus estimate of $30.50 million. Spectrum Pharmaceuticals had a negative return on equity of 30.95% and a negative net margin of 59.33%. Spectrum Pharmaceuticals’s revenue for the quarter was up 1.0% on a year-over-year basis. During the same quarter in the prior year, the business posted ($0.35) earnings per share. On average, equities analysts forecast that Spectrum Pharmaceuticals, Inc. will post ($1.03) EPS for the current year.

A number of large investors have recently added to or reduced their stakes in the business. Piedmont Investment Advisors LLC bought a new position in Spectrum Pharmaceuticals during the 2nd quarter worth approximately $114,000. State Street Corp lifted its holdings in Spectrum Pharmaceuticals by 28.3% during the 2nd quarter. State Street Corp now owns 3,020,563 shares of the biotechnology company’s stock worth $22,507,000 after buying an additional 666,605 shares during the last quarter. Cornerstone Capital Management Holdings LLC. lifted its holdings in Spectrum Pharmaceuticals by 196.5% during the 2nd quarter. Cornerstone Capital Management Holdings LLC. now owns 187,697 shares of the biotechnology company’s stock worth $1,397,000 after buying an additional 124,383 shares during the last quarter. Macquarie Group Ltd. lifted its holdings in Spectrum Pharmaceuticals by 9.4% during the 2nd quarter. Macquarie Group Ltd. now owns 2,247,493 shares of the biotechnology company’s stock worth $16,744,000 after buying an additional 193,883 shares during the last quarter. Finally, PDT Partners LLC lifted its holdings in Spectrum Pharmaceuticals by 15.3% during the 2nd quarter. PDT Partners LLC now owns 142,000 shares of the biotechnology company’s stock worth $1,058,000 after buying an additional 18,800 shares during the last quarter. 66.09% of the stock is currently owned by institutional investors.

TRADEMARK VIOLATION WARNING: “Spectrum Pharmaceuticals, Inc. (SPPI) Sees Large Volume Increase” was posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this piece of content on another site, it was stolen and reposted in violation of United States and international copyright & trademark law. The original version of this piece of content can be accessed at https://www.thecerbatgem.com/2017/09/15/spectrum-pharmaceuticals-inc-sppi-sees-large-volume-increase.html.

Spectrum Pharmaceuticals Company Profile

Spectrum Pharmaceuticals, Inc is a biotechnology company. The Company operates through developing and commercializing oncology and hematology drug products segment. It has a product portfolio consisting of both commercial stage and development stage products that address various cancer types. The Company has six approved oncology/hematology products that target different types of cancer, including non-Hodgkin’s lymphoma (NHL), advanced metastatic colorectal cancer (mCRC), acute lymphoblastic leukemia (ALL) and multiple myeloma (MM).

Receive News & Stock Ratings for Spectrum Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spectrum Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.